Rifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysis.
<h4>Background</h4>In Uganda, isoniazid plus ethambutol is used for 6 months (6HE) during the continuation treatment phase of new tuberculosis (TB) cases. However, the World Health Organization (WHO) recommends using isoniazid plus rifampicin for 4 months (4HR) instead of 6HE. We compare...
Guardado en:
Autores principales: | Yukari C Manabe, Sabine M Hermans, Mohammed Lamorde, Barbara Castelnuovo, C Daniel Mullins, Andreas Kuznik |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c758d8673f4d471f8d969bb25ba89a2b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda.
por: Lisa Nkatha Micheni, et al.
Publicado: (2021) -
Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda
por: Lisa Nkatha Micheni, et al.
Publicado: (2021) -
Rifampicin-Induced Nephrotoxicity in a Tuberculosis Patient: Treatment Dilemma?
por: Antonio Grilo Novais, et al.
Publicado: (2021) -
Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
por: Florence O Bada, et al.
Publicado: (2020) -
Spectrum of antibiotic resistance in UTI caused by Escherichia coli among HIV-infected patients in Uganda: a cross-sectional study
por: George Abongomera, et al.
Publicado: (2021)